• Lovastatin Workflows for Mevalonate Research

  2026-08-24

  Lovastatin is a pathway-level probe for connecting HMG-CoA reductase inhibition with cholesterol metabolism, proliferation, apoptosis, and macrophage clearance. This practical guide translates its concentration- and time-dependent behavior into assay workflows while using a recent plant meristem study to illustrate rigorous temporal and orthogonal experimental design.

• Lovastatin for Reliable Cell Assays

  2026-08-24

  Learn how Lovastatin (SKU A4365) can be used to design, optimize, and interpret cell viability, proliferation, and cytotoxicity assays. This scenario-based guide connects mechanism, solvent handling, concentration selection, and supplier evaluation to documented quantitative data.

• Thymoquinone Limits Doxorubicin Cardiotoxicity

  2026-08-23

  A mouse study reports that Thymoquinone protects cardiac function during doxorubicin exposure and associates this effect with Nrf2/HO-1 signaling, improved redox status, and reduced ferroptosis-related injury. The findings provide a useful preclinical framework for studying cardioprotection while leaving pathway causality, pharmacokinetics, and preservation of doxorubicin antitumor activity unresolved.

• Biotin Azide for CuAAC Biotinylation

  2026-08-22

  Biotin Azide is a terminal-alkyne labeling reagent for copper-catalyzed click chemistry. Its covalently attached biotin supports streptavidin-based detection, affinity purification, and imaging of labeled biomolecules under appropriately optimized aqueous conditions.

• Triazole ALDH2 Activators for Myocardial Ischemia

  2026-08-22

  The reference study reports a triazole-based series of aldehyde dehydrogenase 2 activators designed with molecular simulation to improve both activity and water solubility. Lead compound Z17 produced record-setting ALDH2 activation in vitro and improved cardiac function and biochemical injury markers in a mouse ischemia–reperfusion model, supporting further preclinical development while leaving pharmacokinetic and clinical questions unresolved.

• SIRT1/2 Inhibitor IV: Ran Lactylation Workflows

  2026-08-21

  SIRT1/2 Inhibitor IV (cambinol) provides a cell-permeable pharmacologic perturbation for linking sirtuin activity with Ran lactylation, STAT3 transport, acetylation, and stress responses. This workflow-focused guide shows how to use it alongside lactate manipulation, OGD/R, p53, tubulin, and apoptosis readouts while controlling for dual-target and dose-related limitations.

• Developmental SSRI Exposure and Mu Opioid Signaling

  2026-08-20

  This dissertation identifies a selective motivational deficit after developmental SSRI exposure: mice work less for reward, while reward liking and Pavlovian learning remain comparatively preserved. Pharmacological antagonism or viral knockdown of mu opioid receptors in the nucleus accumbens attenuated the deficit, highlighting opioid–serotonin interactions as a mechanistic direction for depression research.

• Stattic: Practical STAT3 Inhibitor Workflows

  2026-08-20

  Stattic is a small-molecule STAT3 inhibitor for connecting pathway engagement with apoptosis, therapy resistance, and radiation response. This workflow uses validated HNSCC performance data and the microbiome–NF-κB–IL6–STAT3 findings from prostate cancer research to design stronger, better-controlled experiments.

• FCCP Workflows for Mitochondrial and HIF Studies

  2026-08-19

  FCCP enables controlled disruption of oxidative phosphorylation to connect oxygen consumption, ATP production, and hypoxia signaling in cell-based experiments. This guide translates that perturbation into reproducible workflows and shows how it can complement emerging research on mitochondria-derived pre-peroxisomes.

• Dimethyloxalylglycine (DMOG) Protocol Guide

  2026-08-19

  Dimethyloxalylglycine (DMOG), SKU A4506, provides a practical way to induce hypoxia-inducible factor stabilization in cell-based oxygen-sensing, hypoxia signaling, and inflammation studies. It is intended for scientific research only; product-dossier guidance should not be treated as a validated clinical, diagnostic, or universal in vivo dosing protocol.

• Cimetidine for BBB and Cancer Research Workflows

  2026-08-18

  Cimetidine connects a mechanistically distinctive H2-receptor tool with paired MOCK/MDR1 barrier assays and gastrointestinal cancer studies. This workflow emphasizes solvent control, bidirectional transport, recovery correction, and careful interpretation of partial agonism rather than treating the compound as a generic acid-suppression reagent.

• MDockPeP2_VS for Peptide Inhibitor Discovery

  2026-08-18

  The 2024 PNAS Nexus study introduces MDockPeP2_VS, a structure-based workflow that reduces the conformational search burden in large-scale peptide screening by combining molecular docking with structural conservation. Applied to TEM-1 β-lactamase, the method identified TF7 as an experimentally active inhibitor, providing a computational route toward new tools for β-lactam antibiotic resistance research.

• Cimetidine Workflows for H2 and BBB Research

  2026-08-17

  Build reproducible Cimetidine assays for H2 receptor signaling, gastric acid secretion inhibition, and translational cancer research. A validated surrogate BBB workflow adds bidirectional transport, efflux, recovery, and lysosomal-trapping checks without overstating what has been demonstrated for Cimetidine itself.

• JXY, TLR4, and M1 Macrophages in CAC

  2026-08-17

  Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like state through TLR4-associated signaling. The study combines an orthotopic cancer model with cellular, molecular, and pharmacological analyses, providing a mechanistic framework for interpreting immune modulation in inflammation-driven colorectal tumorigenesis.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-08-16

  The PKH26 Red Fluorescent Cell Linker Kit provides a membrane-focused red fluorescent label for tracing cells and monitoring signal partitioning during proliferation studies. It is intended for cell membrane lipid-region labeling in vitro and in vivo, not for intracellular structures or non-membrane targets.

8670 records 1/578 page Next 12345 下5页 Last page